Transparency Market Research Report Added "Benign Prostatic Hyperplasia Therapeutics Market" to its database.

Albany, NY -- (SBWire) -- 03/16/2016 --Transparency Market Research, in a report, titled "Benign Prostatic Hyperplasia (BPH) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," states that the rise in aging population, the surge in the prevalence of urological disorders, and the growing awareness about these illnesses have driven the global benign prostatic hyperplasia (BPH) therapeutics market. In contrast, the increasing adoption rate of minimally invasive surgeries threatens to hamper the expansion of the BPH market.

The report lists a number of medical therapies used for the treatment of benign prostatic hyperplasia. These include phosphodiesterase-5 enzyme inhibitors, nonselective alpha-blockers, alpha-blockers, alpha-adrenergic blockers, 5-alpha-reductase inhibitors (5-ARIs), and anticholinergic agents. The report also studies the leading surgical interventions used to treat benign prostatic hyperplasia. These include transurethral vaporization of the prostate, open prostatectomy, transurethral resection of the prostate, transurethral incision of the prostate, holmium laser resection of the prostate, and photoselective vaporization of the prostate.

With the help of the Porter's five forces analysis model, the report gives readers a better understanding of the bargaining power of buyers and suppliers in the benign prostatic hyperplasia therapeutics market, the threat of new entrants and substitutes, and the degree of competition among the existing market players. A review of the macro and micro factors that might be crucial for these players has also been included in the value chain analysis.

Brochure Download: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1872

The benign prostatic hyperplasia therapeutics market is geographically divided into Asia Pacific, North America, Europe, and Rest of the World. The increased prevalence of lower urinary tract symptoms and benign prostatic hyperplasia has driven North America to be the largest market for benign prostatic hyperplasia therapeutics market. Various surveys and studies have shown that an estimated 14 million men in the US present symptoms for benign prostatic hyperplasia and approximately 90% of men between the age of 45 and 80 suffer from some form of lower urinary tract symptoms. Asia Pacific is also anticipated to exhibit a strong CAGR from 2013 to 2019 thanks to the surge in various urological complications.

The assessment of the vendor landscape of the global benign prostatic hyperplasia therapeutics market makes for an interesting and informative read as the report not only identifies the key players competing in the market but also reviews their performance and contribution over the years. Protox Therapeutics Inc., Ipsen S.A., Nymox Pharmaceutical Corporation, Eli Lilly and Company, Astellas Pharma Inc., AEternaZentaris Inc., EndoCeutics, Inc., Quest PharmaTech Inc., and IntelGenx Technologies Corp are some of the major players vying for the top spot in the benign prostatic hyperplasia therapeutics market.

Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/